Skip to content

4D CT Scan Versus 3D CT Scan Concerning Cardiac Dosimetry Assesment for Left Sided Breast Cancers Radiotherapy

4D CT Scan With Respiratory Gating Versus 3D CT Scan Concerning Cardiac Dosimetry Assesment for Left Sided Breast Cancers Radiotherapy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05726604
Acronym
RD3D4
Enrollment
15
Registered
2023-02-14
Start date
2023-03-02
Completion date
2023-06-15
Last updated
2023-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Cardiac Ischemia, LAD (Left Anterior Descending) Coronary Artery Stenosis, Left Anterior Descending Coronary Artery Stenosis, Left Sided Breast Cancer, Radiation-Induced Vascular Disease, Radiotherapy Side Effect

Keywords

breast cancer

Brief summary

To establish if the cardiac radiation dose assesment is well aproximated with routine 3D CT scan compared to 4D CT experimental scan with respiratory gating (breath motion monitoring). The study population relates to left side breast cancers female patients that require a radiation therapy treatment.

Detailed description

As a standard of care, the postoperative breast cancers radiation therapy is generally based on a 3 dimensions CT scan that does not incorporate the breathing motion by definition. Meanwhile, the patients must commonly receive the treatment in free motion breathing condition. More of that, the Cardiac dose, especially the LAD (left anterior descending artery) dose has been established as the main cause of radiation induced ischemic heart disease (RIHD) and should be consider in the first place. In more concrete terms, the higher the LAD dose is, the greater the RIHD relates: arise the LAD dose by 1 Gy means a 7.4% higher risk to cause a RIHD during the next 5 years. That being said, to determine if the cardiac dosimetry and the dose-volume histograms (specifically for the left side breast cancer treatments including or not the internal mammary artery) obtained from a 3D CT scan reflect well or not the reality (which is widely subject to the breathing motion). Finally, because it has been established that a 4D CT scan can monitor the breathing motion, it seems definitely interesting to compare it with the average 3D CT scan to address this concern.

Interventions

OTHERRespiratory gating

10 minutes breathing motion monitoring during an additional CT scan to establish a more accurate cardiac and LAD dosimetry compared to reality

Sponsors

Central Hospital Saint Quentin
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age ≥ 18 yo 2. Sex=female 3. Patients diagnoses with a left side breast cancer for which a radiation therapy is indicated and confirmed in a multidisciplinary consultation meeting. 4. Be able to understand and give her personal free consent, no judicial protection measure. 5. Written or oral consent, in compliance with the clinical investigation rules and regulation. 6. Patient affiliated with social security system 7. Treatment expected to be realized in Saint Quentin Hospital

Exclusion criteria

1. Patient \< 18 yo 2. Pregnant women. 3. Breastfeeding women. 4. Consent not given 5. Claustrophobia 6. Incapacited subject or judicial protection measure 7. Other research with exclusion period time ongoing 8. All the inclusion criteria not met

Design outcomes

Primary

MeasureTime frameDescription
3D LAD mean dose vs 4D LAD mean dose1 weekTo determine if the mean LAD (left anterior descending artery) dose significantly changes statistically between an usual 3D CT scan versus a 4D CT with breathing motion monitoring (10 breathing phases are monitored). Based on stastical test with 95% confidence intervals, to evaluate if there is a significant difference between 4D CT LAD mean dose and 3D CT LAD mean dose.

Countries

France

Contacts

Primary ContactKarim Boulanouar
ak.boulanouar@ch-stquentin.fr0323067861
Backup ContactFarid BELKHIR, MD
vince07.me@gmail.com0636967657

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026